Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy

J Grebely; B Conway; EB Cunningham; C Fraser; A Moriggia; E Gane; C Stedman; C Cooper; E Castro; P Schmid; K Petoumenos; B Hajarizadeh; P Marks; A Erratt; O Dalgard; K Lacombe; JJ Feld; J Bruneau; JP Daulouede; J Powis; P Bruggmann; GV Matthews; I Kronborg; D Shaw; A Dunlop; M Hellard; TL Applegate; S Crawford; GJ Dore

Journal article

Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy

J Grebely, B Conway, EB Cunningham, C Fraser, A Moriggia, E Gane, C Stedman, C Cooper, E Castro, P Schmid, K Petoumenos, B Hajarizadeh, P Marks, A Erratt, O Dalgard, K Lacombe, JJ Feld, J Bruneau, JP Daulouede, J Powis Show all

International Journal of Drug Policy | ELSEVIER SCIENCE BV | Published : 2018

DOI: 10.1016/j.drugpo.2018.10.004

Abstract

Background: Direct-acting antiviral therapy for hepatitis C virus (HCV) infection is safe and effective, but there are little data among people who have recently injected drugs. This study evaluated the efficacy, and safety of paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin for chronic HCV genotype (G) 1 among people with recent injecting drug use and/or receiving OST. Methods: D3FEAT is an international open-label study that recruited treatment-naïve participants with recent injecting drug use (previous 6 months) and/or receiving OST with chronic HCV G1 infection between June 2016 and February 2017 in seven countries. Participants received paritaprevir/ritonavir, omb..

View full abstract

University of Melbourne Researchers

Margaret Hellard Author

Grants

Funding Acknowledgements

We would also like to acknowledge Ronald D'Amico, Barbara McGovern, Jonathan Anderson, Ze Zhong, Fiona Keane, Fernando Tatsch and others at AbbVie for their support with the study. This work was supported by funding from AbbVie. The sponsors had no role in the analysis and interpretation of the study results. The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. JG is supported by a National Health and Medical Research Council Career Development Fellowship. GD is supported by a National Health and Medical Research Council Practitioner Research Fellowship. BH is supported by a National Health and Medical Research Council Early Career Fellowship.